These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18835148)

  • 1. 'Towards a global approach'--an overview of Harm Reduction 2008: IHRA's 19th International Conference.
    Fraser S; Hopwood M; Madden A; Treloar C
    Int J Drug Policy; 2009 Jan; 20(1):93-7. PubMed ID: 18835148
    [No Abstract]   [Full Text] [Related]  

  • 2. How the harm reduction movement contrasts itself against punitive prohibition.
    Tammi T; Hurme T
    Int J Drug Policy; 2007 Mar; 18(2):84-7. PubMed ID: 17689349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation challenges: an overview of Harm Reduction 2010, IHRA's 21st conference.
    Russell SJ; McVeigh J
    Int J Drug Policy; 2011 Jan; 22(1):82-6. PubMed ID: 21242084
    [No Abstract]   [Full Text] [Related]  

  • 4. Using words: the harm reduction conception of drug use and drug users.
    Stafford N
    Int J Drug Policy; 2007 Mar; 18(2):88-91. PubMed ID: 17689350
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining a service for people who use drugs as 'low-threshold': what should be the criteria?
    Mofizul Islam M; Topp L; Conigrave KM; Day CA
    Int J Drug Policy; 2013 May; 24(3):220-2. PubMed ID: 23567101
    [No Abstract]   [Full Text] [Related]  

  • 6. The rights of drug treatment patients: Experience of addiction treatment in Poland from a human rights perspective.
    Klingemann J
    Int J Drug Policy; 2017 May; 43():67-73. PubMed ID: 28231439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.
    Marshall BD; Green TC; Yedinak JL; Hadland SE
    Int J Drug Policy; 2016 May; 31():25-31. PubMed ID: 26919826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stigmatizing harm reduction through language: a case study into the use of "addict" and opposition to supervised injection sites in Canada.
    Cortina SC
    J Addict Nurs; 2013; 24(2):102-7. PubMed ID: 24621488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harm reduction coming of age: A summary of the '18th International Conference on the Reduction of Drug Related Harm'-Warsaw, Poland: 13-17 May 2007.
    Moskalewicz J; Barrett D; Bujalski M; Dabrowska K; Klingemann H; Klingemann J; Malczewski A; Struzik M
    Int J Drug Policy; 2007 Dec; 18(6):503-8. PubMed ID: 18061432
    [No Abstract]   [Full Text] [Related]  

  • 10. Harm reduction and the global drug control regime: contemporary problems and future prospects.
    Bewley-Taylor DR
    Drug Alcohol Rev; 2004 Dec; 23(4):483-9. PubMed ID: 15763753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participatory research with an online drug forum: a survey of user characteristics, information sharing, and harm reduction views.
    Chiauzzi E; Dasmahapatra P; Lobo K; Barratt MJ
    Subst Use Misuse; 2013 Jun; 48(8):661-70. PubMed ID: 23750771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The social logic of naloxone: Peer administration, harm reduction, and the transformation of social policy.
    Faulkner-Gurstein R
    Soc Sci Med; 2017 May; 180():20-27. PubMed ID: 28315595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sameness and difference: metaphor and politics in the constitution of addiction, social exclusion and gender in Australian and Swedish drug policy.
    Moore D; Fraser S; Törrönen J; Tinghög ME
    Int J Drug Policy; 2015 Apr; 26(4):420-8. PubMed ID: 25662895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a sociology of normal substance use.
    Hammersley R
    Int J Drug Policy; 2011 Nov; 22(6):413-4. PubMed ID: 22104588
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug policy, harm and human rights: a rationalist approach.
    Stevens A
    Int J Drug Policy; 2011 May; 22(3):233-8. PubMed ID: 21481578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outreach-based drug treatment for sex trading women: the Cal-Pep risk-reduction demonstration project.
    Bowser BP; Ryan L; Smith CD; Lockett G
    Int J Drug Policy; 2008 Dec; 19(6):492-5. PubMed ID: 18375110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From harm reduction to human rights: bringing liberalism back into drug reform debates.
    Hathaway AD
    Drug Alcohol Rev; 2002 Dec; 21(4):397-404. PubMed ID: 12537711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a brighter future.
    Mooney H
    Health Serv J; 2012 Jul; 122(6314):20-2. PubMed ID: 22950250
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimal timing of use reduction vs. harm reduction in a drug epidemic model.
    Caulkins JP; Tragler G; Wallner D
    Int J Drug Policy; 2009 Nov; 20(6):480-7. PubMed ID: 19361975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization and harm reduction: research avenues and policy agendas.
    Erickson PG; Hathaway AD
    Int J Drug Policy; 2010 Mar; 21(2):137-9. PubMed ID: 20022234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.